<table border="1"><tr><th>IUPAC</th><td><ul><li>N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-2-propanyl)-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide</li></ul></td></tr><tr><th>Bruto Formula</th><td><ul><li>C | 20 | H | 21 | FN | 6 | O | 5</li></ul></td></tr><tr><th>CAS</th><td><ul><li>518048-05-0</li></ul></td></tr><tr><th>PubChem</th><td><ul><li>54671008</li></ul></td></tr><tr><th>DrugBank</th><td><ul><li>DB06817</li></ul></td></tr><tr><th>ATH</th><td><ul><li>J05AJ01</li></ul></td></tr><tr><th>Bioavailable.</th><td><ul><li>60% (FDA)</li></ul></td></tr><tr><th>Contact with plasma proteins</th><td><ul><li>83%</li></ul></td></tr><tr><th>Metabolism</th><td><ul><li>Pechenetic (UGT1A1)</li></ul></td></tr><tr><th>Period of semi-translation.</th><td><ul><li>9 hours</li></ul></td></tr><tr><th>Excretion</th><td><ul><li>feces and urine</li></ul></td></tr><tr><th>Methods of introduction</th><td><ul><li>Perorally</li></ul></td></tr></table>